Price-to-Projected Revenue Ratio: Repligen (RGEN)
Repligen Corporation (RGEN) generates revenue by supplying high-tech filtration and chromatography systems for vaccine production. The forward P/S multiple on GURU.Markets contains data where 13.20 describes the current status of the metric. Management's strategy is based on acquiring breakthrough biotechnologies, while stringent FDA certification creates an insurmountable barrier to entry for new players in this segment.
RGEN (Repligen Inc.): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock exchange capitalization indicators:
- book value of equity indicators:
- debt and liquidity data:
- business earnings and investment ratios data:
RGEN - Net Financial Result|Expected Profit Repligen Corporation|RGEN - Market Cap to Earnings|Future Price to Earnings Repligen Corp.|RGEN - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Repligen Inc.|RGEN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Repligen|RGEN - Net earnings per share for the trailing year|Quarterly EPS earnings growth repligen.com|RGEN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Repligen Corporation
- company sales and revenue statistics:
Summary company analysis:Repligen RGEN
The forward P/S ratio determines the market value of a business relative to expected annual sales, allowing an investor to assess the extent of the premium paid for future cash flows. By analyzing the issuer's projected P/S, you can see the capitalization dynamics of Repligen Corporation (RGEN) based on market expectations for biopharmaceutical equipment demand and regulatory approval of new drugs, both of which critically impact the company's revenue.
Competitors of Repligen Corporation
Forward P/S Multiple TEM (Tempus AI, Inc.)|QGEN - Forward Price-to-Revenue Multiple|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Avidity Corp|CRISPR Therapeutics AG (CRSP) - Price-to-Projected Revenue Ratio|genedx.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Ultragenyx|Beam Therapeutics Inc - Future Price to Revenue|Price-to-Projected Revenue Ratio Sarepta Therapeutics Inc (SRPT)|TWST - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio 10x Genomics, Inc. TXG|Forward Price to Sales NTLA|Stoke Therapeutics, Inc. - Forward P/S Multiple|BLFS - Forward P/S Multiple|WVE (Wave Life Sciences Corp) - Forward Price-to-Revenue Multiple|MAZE: Price to Expected Revenue Ratio|SION (Sionna Therapeutics Inc) - Forward P/S Multiple|primemedicine.com (PRME) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|QURE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio MeiraGTx PLC MGTX|RGNX: Market Cap to Projected Revenue|SLDB - Price-to-Projected Revenue Ratio|Forward Price to Sales OCGN (ocugen.com)|PACB: Forward P/S Multiple|Projected Price to Revenue Benitec Biopharma Inc BNTC|DSGN (Design Pharma) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Rocket Corp RCKT|Price-to-Projected Revenue Ratio 4D Molecular Therapeutics (FDMT)|lexeotx.com - Market Cap to Projected Revenue|Forward P/S Multiple KRRO (Korro Bio)|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|PRQR (ProQR Therapeutics N.V.) - Market Cap to Projected Revenue|CDXS: Forward P/S Multiple|sangamo.com (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Biotechnology, Inc.|MGX: Forward Price to Sales|Forward P/S Multiple DTIL|GBIO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|XCUR (Exicure Inc.) - Future Price to Revenue|IMNN - Price-to-Projected Revenue Ratio|PHIO: Price-to-Projected Revenue Ratio|MBIO: Forward P/S Multiple|RNAZ - Market Cap to Expected Sales Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|APDN - Projected Price to Revenue|Forward P/S Multiple BLUE|IPA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omega OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (syros.com)|TBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple TRACON Pharmaceuticals Inc.|Price-to-Projected Revenue Ratio Unity Bio
